Eli Lilly ( NYSE: LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling ...

fueled by the demand for diabetes and weight loss drugs, known generically as tirzepatide and semaglutide. The suit challenges a key strategy that has allowed compounding pharmacies to continue to ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

As the Food and Drug Administration cracks down on compounded versions of popular weight loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide), Americans who rely on these cheaper medications ...

Novo Nordisk, the pharmaceutical giant that makes Ozempic and Wegovy, emphasizes there is no generic semaglutide currently ... What to do if you rely on compounded weight-loss drugs There are ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

In 2022, the FDA announced there was a shortage of the brand-name medications, which allowed compounding pharmacies to make generic semaglutide, the main active ingredient in the weight-loss drugs.